NextCure, Inc. Common Stock
NXTCNextCure, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapies to treat cancer. Founded to leverage groundbreaking research in immunology, the company aims to discover and develop novel monoclonal antibodies that can modulate immune responses and improve outcomes for cancer patients.
Company News
Law firm Halper Sadeh LLC is investigating whether NextCure, Inc. obtained a fair price in its proposed merger with Avere Therapeutics, where NextCure shareholders would own only approximately 1.21% of the combined company. The investigation examines potential violations of federal securities laws and breaches of fiduciary duty regarding fair pri...
NextCure Inc. announced a definitive merger agreement with privately-held Avere Therapeutics in an all-stock transaction. The combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker 'AVRX'. Avere's lead program AVR-001, an oral IL-23 receptor antagonist, received $320 million in concurrent private investment. The merg...
NextCure (NASDAQ: NXTC) shares rose 2.10% in premarket trading Wednesday following positive Phase 1 clinical data for SIM0505, an antibody-drug conjugate developed with Simcere Zaiming Pharmaceutical for treating platinum-resistant ovarian cancer and uterine serous carcinoma. However, the stock remains deeply oversold with technical indicators sh...
NextCure announced Phase 1 dose escalation data for SIM0505 (CDH6 ADC) expected in Q2 2026 and expanded higher dose cohorts for LNCB74 (B7-H4 ADC). The company reported preliminary year-end 2025 cash position of $41.8 million and expects resources to fund operations into the first half of 2027. LNCB74 proof-of-concept data timeline was delayed to...
NextCure reported a Q2 2025 net loss of $26.8 million, primarily due to a $17.0 million license fee for SIM0505. The company advanced its lead clinical programs LNCB74 and SIM0505, with proof-of-concept data expected in the first half of 2026.
